Celcuity Valuation Multiples

Celcuity Overview

About Celcuity

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company’s lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

Founded

2011

HQ

Employees

87

Website

celcuity.com

Sectors

BiopharmaceuticalsDiagnostics & GenomicsBioTech

Financials (LTM)

Revenue: $12M

EBITDA: ($176M)

EV

$5B

Valuation Multiples

Multiples.vc

Start free trial

Celcuity Financials

Celcuity reported last 12-month revenue of $12M and negative EBITDA of ($176M).

In the same LTM period, Celcuity generated $10M in gross profit, ($176M) in EBITDA losses, and had net loss of ($180M).

Celcuity P&L

In the most recent fiscal year, Celcuity reported revenue of — and EBITDA of ($101M).

Celcuity expects next 12-month revenue of XXX and NTM EBITDA of XXX

Celcuity Stock Performance

Celcuity has current market cap of $5B, and enterprise value of $5B.

Celcuity's stock price is $113.61.

Celcuity Valuation Multiples

Celcuity trades at 428.0x EV/Revenue multiple, and (29.1x) EV/EBITDA.

Celcuity Financial Valuation Multiples

As of March 21, 2026, Celcuity has market cap of $5B and EV of $5B.

Equity research analysts estimate Celcuity's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Celcuity has a P/E ratio of (29.2x).

Celcuity Margins & Growth Rates

Celcuity's revenue in the last 12 month grew by 907%.

Celcuity's revenue per employee in the last FY averaged $0.1M.

Celcuity's rule of 40 is (565%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Celcuity's rule of X is 796% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Celcuity Public Comps

See public comps and valuation multiples for other Biopharmaceuticals and Diagnostics & Genomics comps.

Celcuity M&A Activity

Celcuity acquired XXX companies to date.

Last acquisition by Celcuity was on XXXXXXXX, XXXXX. Celcuity acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Celcuity Investment Activity

Celcuity invested in XXX companies to date.

Celcuity made its latest investment on XXXXXXXX, XXXXX. Celcuity invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).